Literature DB >> 2471116

Detection of Epstein-Barr virus in CNS lymphomas by in-situ hybridization.

R M Bashir1, N L Harris, F H Hochberg, R M Singer.   

Abstract

We used an optimized in-situ hybridization technique employing a biotinylated Epstein-Barr (EB) virus sequence, BamH1V (3.1 kb), to detect this sequence in 2 EB virus-infected cell lines (B95-8 and Namalwa) and 8 CNS lymphomas. We obtained a good hybridization signal from cytospins of B95-8 (EB virus productively infected) and Namalwa (EB virus latently infected, 1 copy per cell) cell lines. We were able to detect signal from both cell lines after overnight fixation in 10% formalin and paraffin embedding, but development time in the detection chromogen required longer incubation and the signal intensity was lower than in cytospin cells. We then used the technique to examine formalin-fixed, paraffin-embedded primary CNS lymphoma tissue from 4 patients who were immunocompromised (1 renal transplant, 3 acquired immune deficiency syndrome) and 4 patients who were not. All 4 CNS lymphomas from immunocompromised patients hybridized well with BamH1V, exhibiting a pattern of staining similar to Namalwa cells and nonlytically infected B95-8 cells. There was no relationship between the intensity and degree of reaction and the patients' survival. None of the 4 CNS lymphomas in immunocompetent patients or uninvolved brain showed any reactivity with BamH1V. We suggest that low-abundance targets are detectable in paraffin-embedded tissue by in-situ hybridization using biotinylated probes. Detection of EB viral sequences in CNS lymphomas in immunocompromised patients suggests a role for the virus in the pathogenesis of this tumor.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2471116     DOI: 10.1212/wnl.39.6.813

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  15 in total

1.  Detection of Epstein-Barr virus by in situ hybridization. Progress toward development of a nonisotopic diagnostic test.

Authors:  R Bashir; F Hochberg; R H Singer
Journal:  Am J Pathol       Date:  1989-12       Impact factor: 4.307

2.  Epstein-Barr and human immunodeficiency viruses in acquired immunodeficiency syndrome-related primary central nervous system lymphoma.

Authors:  S Morgello
Journal:  Am J Pathol       Date:  1992-08       Impact factor: 4.307

Review 3.  In situ hybridisation in perspective.

Authors:  A Warford; I Lauder
Journal:  J Clin Pathol       Date:  1991-03       Impact factor: 3.411

4.  Abundant expression of EBER1 small nuclear RNA in nasopharyngeal carcinoma. A morphologically distinctive target for detection of Epstein-Barr virus in formalin-fixed paraffin-embedded carcinoma specimens.

Authors:  T C Wu; R B Mann; J I Epstein; E MacMahon; W A Lee; P Charache; S D Hayward; R J Kurman; G S Hayward; R F Ambinder
Journal:  Am J Pathol       Date:  1991-06       Impact factor: 4.307

5.  Membranous changes in primary malignant CNS lymphomas.

Authors:  F Slowik; K Jellinger
Journal:  Acta Neuropathol       Date:  1989       Impact factor: 17.088

Review 6.  HIV-associated neurological disorders: a guide to pharmacotherapy.

Authors:  Ik L Tan; Justin C McArthur
Journal:  CNS Drugs       Date:  2012-02-01       Impact factor: 5.749

7.  Epstein-Barr virus and brain lymphomas.

Authors:  R M Bashir; F H Hochberg; M X Wei
Journal:  J Neurooncol       Date:  1995       Impact factor: 4.130

8.  Detection of Eber-1 RNA in primary brain lymphomas in immunocompetent and immunocompromised patients.

Authors:  R Bashir; B McManus; C Cunningham; D Weisenburger; F Hochberg
Journal:  J Neurooncol       Date:  1994       Impact factor: 4.130

9.  Detection of Epstein-Barr virus genomes in AIDS related lymphomas: sensitivity and specificity of in situ hybridisation compared with Southern blotting.

Authors:  S J Hamilton-Dutoit; H J Delecluse; M Raphael; G Lenoir; G Pallesen
Journal:  J Clin Pathol       Date:  1991-08       Impact factor: 3.411

Review 10.  Primary central nervous system lymphomas--an update.

Authors:  K A Jellinger; W Paulus
Journal:  J Cancer Res Clin Oncol       Date:  1992       Impact factor: 4.553

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.